Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1630763 | 0.86 | CCR9 (0.63) | CCR9HSD17B2 | |
| SCHEMBL2629495 | 0.85 | CCR9 (0.54) | CCR9HSD17B2 | |
| SCHEMBL1630982 | 0.80 | HSD17B2 (0.61) | CCR9HSD17B2 | |
| SCHEMBL344317 | 0.78 | CCR9 (0.58) | CCR9HSD17B2 | |
| SCHEMBL1630066 | 0.77 | CCR9 (0.57) | CCR9HSD17B2 | |
| SCHEMBL343333 | 0.77 | CCR9 (0.82) | CCR9 | |
| SCHEMBL1630530 | 0.76 | HSD17B2 (0.57) | CCR9HSD17B2 | |
| SCHEMBL1630161 | 0.76 | CCR9 (0.55) | CCR9HSD17B2 | |
| SCHEMBL1631935 | 0.75 | CCR9 (0.66) | CCR9HSD17B2 | |
| SCHEMBL343772 | 0.75 | CCR9 (0.69) | CCR9HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101097-A9 | ARYL SULFONAMIDES | UNGASHE SOLOMON (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101097-A9 | ARYL SULFONAMIDES | UNGASHE SOLOMON (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101097-A9 | ARYL SULFONAMIDES | UNGASHE SOLOMON (US) | 2012-04-26 | — | — | US | disclosed |
| US-20110201610-A1 | ARYL SULFONAMIDES | UNGASHE SOLOMON | 2011-08-18 | — | — | US | disclosed |
| US-20110201610-A1 | ARYL SULFONAMIDES | UNGASHE SOLOMON | 2011-08-18 | — | — | US | disclosed |
| US-20110201610-A1 | ARYL SULFONAMIDES | UNGASHE SOLOMON | 2011-08-18 | — | — | US | disclosed |
| US-7932252-B2 | CCR9 chemokine receptor modulators; treating inflammatory and immune diseases; inhibit the binding of chemokines, such as TECK (thymus-expressed chemokine), to the CCR9 receptor; 1-arylsulfonamido-2-aryl(alkyl)benzene compounds | CHEMOCENTRYX, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932252-B2 | CCR9 chemokine receptor modulators; treating inflammatory and immune diseases; inhibit the binding of chemokines, such as TECK (thymus-expressed chemokine), to the CCR9 receptor; 1-arylsulfonamido-2-aryl(alkyl)benzene compounds | CHEMOCENTRYX, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932252-B2 | CCR9 chemokine receptor modulators; treating inflammatory and immune diseases; inhibit the binding of chemokines, such as TECK (thymus-expressed chemokine), to the CCR9 receptor; 1-arylsulfonamido-2-aryl(alkyl)benzene compounds | CHEMOCENTRYX, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-20080161345-A1 | Aryl Sulfonamides | CHEMOCENTRYX, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161345-A1 | Aryl Sulfonamides | CHEMOCENTRYX, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161345-A1 | Aryl Sulfonamides | CHEMOCENTRYX, INC. | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201610-A1 | ARYL SULFONAMIDES | CCR2, CCL2, CX3CR1 | CCR9 13/4885HSD17B2 1750/4885 |
| US-20080161345-A1 | Aryl Sulfonamides | CCR2, CCL2, CX3CR1 | CCR9 13/4885HSD17B2 1750/4885 |
| US-20120101097-A9 | ARYL SULFONAMIDES | CCR2, CCL2, CX3CR1 | CCR9 13/4885HSD17B2 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.